CDDO Methyl Ester is an agonist for the KEAP1-Nrf2 pathway. Provided as 5mg of dry powder.
CDDO Methyl Ester (bardoxolone methyl) is a semi-synthetic triterpenoid developed from the oleanolic acid scaffold that induces apoptosis and differentiation in tumor cells. Agonist of the KEAP1-Nrf2 pathway, thus inducing expression of antioxidant proteins and protection against oxidative damage from injury and inflammation. Also an antagonist of the NF-kB pro-inflammatory transcription factor and PPARG. Underwent clinical trials for type 2 diabetes treatment, due to its potent antidiabetic activity, but was confirmed to enhance cardiac disease during a phase 2 trial in October 2012. Provided as 5mg of dry powder.
| Marque | DiscoverX |
|---|---|
| Réf. B-LABO | BL-RE-170227 |
| Réf. fabricant | 17392469 |
| Quantité | 5 mg |
